FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia

FDA changed its accelerated approval of blinatumomab (Blincyto) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.

Cancer Currents: An NCI Cancer Research Blog